Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema.

IF 2.3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES Therapeutics and Clinical Risk Management Pub Date : 2020-11-06 eCollection Date: 2020-01-01 DOI:10.2147/TCRM.S271184

Athanassios K Giarmoukakis, Styliani V Blazaki, Georgios C Bontzos, Argyro D Plaka, Konstantinos N Seliniotakis, Larissa D Ioannidi, Miltiadis K Tsilimbaris

{"title":"Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema.","authors":"Athanassios K Giarmoukakis, Styliani V Blazaki, Georgios C Bontzos, Argyro D Plaka, Konstantinos N Seliniotakis, Larissa D Ioannidi, Miltiadis K Tsilimbaris","doi":"10.2147/TCRM.S271184","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the effect of twice-daily nepafenac ophthalmic suspension 0.3% on postoperative cystoid-macular-edema (CME).Patients and methods: In this prospective, clinic-based, non-randomized case-series, 21 patients (21 eyes) were enrolled with either acute or chronic postoperative CME after cataract extraction. Patients were treated with twice-daily nepafenac 0.3% drops, and followed for at least a 4-month period. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT)-derived central retinal thickness (CRT) were measured.Results: From 21 patients, eight presented with acute postoperative CME and 13 with chronic CME. Mean follow-up was 4.82±1.24 months. No adverse events were reported during the study. Baseline BCVA was 0.49±0.36 logMAR and improved to 0.36±0.42 logMAR at the last follow-up visit (P<0.005). CRT decreased from 450.40±90.74 μm at baseline to 354.60±81.49 μm (P<0.05), following treatment.Conclusion: Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"16 ","pages":"1067-1074"},"PeriodicalIF":2.3000,"publicationDate":"2020-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TCRM.S271184","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S271184","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 3

Abstract

Purpose: To assess the effect of twice-daily nepafenac ophthalmic suspension 0.3% on postoperative cystoid-macular-edema (CME).

Patients and methods: In this prospective, clinic-based, non-randomized case-series, 21 patients (21 eyes) were enrolled with either acute or chronic postoperative CME after cataract extraction. Patients were treated with twice-daily nepafenac 0.3% drops, and followed for at least a 4-month period. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT)-derived central retinal thickness (CRT) were measured.

Results: From 21 patients, eight presented with acute postoperative CME and 13 with chronic CME. Mean follow-up was 4.82±1.24 months. No adverse events were reported during the study. Baseline BCVA was 0.49±0.36 logMAR and improved to 0.36±0.42 logMAR at the last follow-up visit (P<0.005). CRT decreased from 450.40±90.74 μm at baseline to 354.60±81.49 μm (P<0.05), following treatment.

Conclusion: Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

0.3%外用尼非那酸治疗术后黄斑囊样水肿的疗效观察。

目的:观察每日2次0.3%尼泊芬酸眼悬液对术后黄斑囊样水肿(CME)的影响。患者和方法:在这项前瞻性、临床为基础、非随机的病例系列研究中，21例患者(21只眼)在白内障摘出术后出现急性或慢性CME。患者接受每日两次0.3%尼帕芬酸滴剂治疗，随访至少4个月。测量最佳矫正视力(BCVA)和光谱域光学相干断层扫描(SD-OCT)衍生的视网膜中央厚度(CRT)。结果:21例患者中，8例出现术后急性CME, 13例出现慢性CME。平均随访时间为4.82±1.24个月。研究期间无不良事件报告。基线BCVA为0.49±0.36 logMAR，在最后一次随访时提高到0.36±0.42 logMAR。结论:我们的结果强烈表明，每天两次给予0.3%尼帕芬酸滴剂可能是治疗术后CME的有希望的替代方案。需要进一步的研究来进一步验证我们的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

4.80

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.